Work

Persistent Microcytosis and Incomplete Structured Recognition of Genetically-Defined β-Thalassemia Trait in All of Us

Year: 2026
Type: article
Study design: Observational Study
Abstract: We assessed structured electronic health record evidence of etiologic recognition after persistent microcytosis became visible in genetically defined β-thalassemia carriers. In a genotype-first All of Us cohort, the landmark was the second complete blood count with mean corpuscular volume (MCV) <80 fL; recognition was defined by combined hemoglobinopathy test/result records and thalassemia diagnosis codes. Among carriers lacking evidence at the landmark, adjusted Cox models examined subsequent recognition by functional severity (β++ = 0, β+ = 1, β0 = 2), both before and after adding landmark MCV. Of 1,977 carriers, 852 had repeated complete blood counts, and 793 (93.1%) had persistent microcytosis. At the landmark, 560/793 (70.6%) lacked recognition evidence; 228/560 (40.7%) subsequently acquired it (5-year cumulative probability 32.6%, 95% confidence interval [CI] 28.6–36.9). Greater severity was associated with faster recognition (hazard ratio [HR] 1.37 per severity step, 95% CI 1.10–1.72). With MCV added, the severity HR was 1.15 (95% CI 0.89–1.47); the MCV HR was 0.78 per +5 fL (95% CI 0.66–0.92). Diagnosis-code-only endpoints yielded similar estimates. The documentation gap persisted under stringent observation requirements. Persistent, genotype-consistent microcytosis frequently preceded structured documentation of investigation or diagnosis. Associations with landmark MCV support a link between phenotypic visibility and recorded investigation or diagnosis, not proof of clinical awareness, missed diagnosis, or causal mediation.
Source: Figshare
Author: Ali Hanbashi
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236863323
FWCI:
Cites:
Cited by:
Related to: 10